ClinicalTrials.gg
TerminatedNCT02184260ATISUpdated Jul 10, 2014

Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic Stroke

A Phase 4 interventional study of Metamizole and Placebo in Stroke, sponsored by Boehringer Ingelheim. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-10.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Stroke by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Stroke · Boehringer Ingelheim.

Enrollment
12th of 12
58 · median 686
Started
1998
the only one that year
Phase 4
3 of 23
none open now
Registered
11th of 23
by date

Among the 23 studies in Stroke by Boehringer Ingelheim, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 1998, is one of 3 in phase 4, and was the 11th registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

None of the 23 studies in Stroke by Boehringer Ingelheim is open now. The open studies under Stroke, anywhere →

Who these studies take

Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Stroke by Boehringer Ingelheim as a file.
02

Study summary

Clinical efficacy and safety of Metamizole 2 g i.v. versus placebo, as antithermic therapy in the acute phase of ischemic stroke.

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18 years
  • Hemispherical cerebral infarction with moderate (SSS = 30-44 points) or severe (SSS \< 30 points) deficit at the time of inclusion. However, only patients with a score between 15 and 44 points on the SSS scale will be included
  • Tympanic temperature between 37 and 38 degrees Celsius. The relationship between tympanic and body temperature is as follows: tympanic temperature = body temperature + 0.3 degrees Celsius
  • Onset of cerebral infarction symptoms within the last 24 hours. When the time of onset of symptoms is unknown (e.g. ictus occurred while sleeping) the last time when the patient was asymptomatic will be considered as time of onset
  • Normal cerebral CT scan or with signs of cerebral infarction
  • Patient's written or orally witnessed in accordance with local legislation, guidelines of Good Clinical Practice (GCP) and International Conference on Harmonization (ICH)-GCP

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of granulocytopenia, thrombocytopenia or aplastic blood diseases of any etiology. Known to salicylates, pyrazolones and other nonsteroidal antiinflammatory drugs (NSAIDs). NSAID-induced bronchial asthma
  • Patients with a history indicating a less than 30 days or patients whom the investigator thinks that it will not be possible to follow for entire 30 days
  • Non-cooperative
  • Patients with neurological sequelae of a previous stroke
  • Cerebral hemorrhage
  • Pregnancy, lactation
  • Participation in another clinical trial
  • Intake of acetylsalicylic acid (ASA) > 300 mg per day, paracetamol or NSAIDs during the 24 hours prior to administration of the study medication
  • Seizures at the start of the stroke
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Metamizole

    Drug: Metamizole

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of the functional outcome according to the Scandinavian Stroke Scale (SSS)

    Time frame: after 30 days

Secondary outcomes

  1. Assessment of functional outcome according to SSS

    Time frame: Baseline, after 3 and 7 days

  2. Number of patients with score of SSS < 30 points

    Time frame: after 30 days

  3. Clinical impression assessed on the Modified Rankin Scale

    Time frame: after 30 days

  4. Effect on the activities of daily living assessed on Barthel Index

    Time frame: after 30 days

  5. Number of patients requiring rescue therapy

    Time frame: up to 30 days

  6. Duration of hospital stay

    Time frame: up to 30 days

  7. Assessment of tympanic temperature

    Time frame: up to 3 days after start of treatment

  8. Percentage of mortality

    Time frame: after 30 days

  9. Number of patients with adverse events

    Time frame: up to 30 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 1998 and a primary completion of May 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2014
First posted
Jul 9, 2014
Start
Dec 1998
Primary completionActual
May 2002
Last update
Jul 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02184260
Responsible party
Sponsor
First posted
Jul 9, 2014
Start date
Dec 1998
Primary completion
May 2002
Last update
Jul 10, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dipyrone

Start the discussion